No Data
No Data
No Data
Express News | Sumitomo Pharma America Enters Into a Cooperative Research and Development Agreement With the National Cancer Institute to Advance Clinical Understanding of Enzomenib
Sumitomo Pharma - Sharply declined, concerned about the impact of Pharmaceutical tariffs.
Significant decline. President Trump commented in a speech at an event, "Soon, a large tariff on Pharmaceuticals will be announced." While the imposition of tariffs on Pharmaceuticals is expected, it appears that there will be increased selling pressure on stocks within the Sector that are likely to be impacted. The company has a high revenue composition from North America, where the revenue from North America accounts for 179.4 billion yen of the total revenue of 293.2 billion yen for the fiscal year ending in March 2025.
Express News | Japan's Sumitomo Pharma Shares Down 9.9%
Sumitomo Pharma Extends Executive Pay Cuts Amid Business Challenges
Jefferies Adjusts Sumitomo Pharma's Price Target to 1,100 Yen From 900 Yen, Keeps at Buy
Express News | Sumitomo Pharma Co - Will Extend Period of Reduction in Executive Remuneration as Co Continues to Face Challenging Business Situation